Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Seikagaku initiates phase III study of SI-613 to treat osteoarthritis in Japan

Feb. 6, 2017

Canada first to approve Kevzara

Feb. 1, 2017

Amgen receives positive opinion for biosimilar adalimumab ABP-501

Jan. 30, 2017

EMA committee gives positive opinion for Pfizer's Xeljanz

Jan. 30, 2017

GlaxoSmithKline studies GSK-3117391 for rheumatoid arthritis in phase II trial

Jan. 27, 2017

Mitsubishi Tanabe Pharma discovers MMP-9 production inhibitors

Jan. 25, 2017

WuXi-MedImmune cleared to conduct phase I studies of WBP-216 in China

Jan. 19, 2017

FDA, EMA accept Boehringer Ingelheim's BI-695501 for review

Jan. 19, 2017

Orion presents novel bromodomain-containing protein 4 inhibitors

Jan. 18, 2017

EC grants new orphan drug designation to Corbus' JBT-101

Jan. 18, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...